Generic placeholder image

Current Hypertension Reviews


ISSN (Print): 1573-4021
ISSN (Online): 1875-6506

Management of Prehypertension: Current Status and Future Strategies

Author(s): Hiroyuki Sasamura, Hiroshi Itoh and Stevo Julius

Volume 7, Issue 2, 2011

Page: [118 - 124] Pages: 7

DOI: 10.2174/157340211797457854

Price: $65


Prehypertension is known to be a risk factor for hypertension and cardiovascular disease. If prehypertension is left untreated, the blood pressure continues to increase due to multiple accelerators which facilitate the development of hypertension. Studies using animal models of hypertension suggested that interruption of these mechanisms by transient inhibition of the renin-angiotensin system (RAS) attenuates the development of hypertension. The TROPHY study provided clinical evidence that pharmacological intervention in the prehypertensive stage may suppress subsequent development of hypertension. Recently, we reported that high dose angiotensin inhibition in spontaneously hypertensive rats (SHR) with established hypertension caused a significant regression of hypertension, and we have started a prospective, multi-center clinical study (STAR CAST study) to examine if regression from hypertension back to prehypertension may also be feasible in humans. Since prehypertension is increasingly recognized as an important public health issue, further studies to assess strategies for attenuating the progression from prehypertension to hypertension are required.

Keywords: Prehypertension, high-normal blood pressure, pharmacological therapy, prevention, regression, eutrophic remodeling, chronic inflammation, hypertrophy, angiotensin receptor blockers, pharmacological agents

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy